PMC:7376845 / 3996-4508 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T25","span":{"begin":37,"end":43},"obj":"Body_part"},{"id":"T26","span":{"begin":434,"end":441},"obj":"Body_part"}],"attributes":[{"id":"A25","pred":"fma_id","subj":"T25","obj":"http://purl.org/sig/ont/fma/fma84116"},{"id":"A26","pred":"fma_id","subj":"T26","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"While SARS-CoV-2 shares higher whole-genome sequence identity with bat-SL-CoVZC45 and bat-SL-CoVZXC21 (88–89%) than with SARS-CoV-1 (79–82%), the RBD of SARS-CoV-2 is more similar to SARS-CoV-1 RBD [8,9]. In line with this, several research groups have demonstrated that SARS-CoV-2 utilises the same host receptor, angiotensin-converting enzyme 2 (ACE2), as SARS-CoV-1 for viral entry [3,16-18]. Due to its role in virus entry, the S protein has been the target for the generation of monoclonal antibodies (mAb)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"140","span":{"begin":315,"end":346},"obj":"Gene"},{"id":"141","span":{"begin":348,"end":352},"obj":"Gene"},{"id":"142","span":{"begin":6,"end":16},"obj":"Species"},{"id":"143","span":{"begin":121,"end":129},"obj":"Species"},{"id":"144","span":{"begin":153,"end":163},"obj":"Species"},{"id":"145","span":{"begin":183,"end":191},"obj":"Species"},{"id":"146","span":{"begin":271,"end":281},"obj":"Species"},{"id":"147","span":{"begin":358,"end":366},"obj":"Species"}],"attributes":[{"id":"A140","pred":"tao:has_database_id","subj":"140","obj":"Gene:59272"},{"id":"A141","pred":"tao:has_database_id","subj":"141","obj":"Gene:59272"},{"id":"A142","pred":"tao:has_database_id","subj":"142","obj":"Tax:2697049"},{"id":"A143","pred":"tao:has_database_id","subj":"143","obj":"Tax:694009"},{"id":"A144","pred":"tao:has_database_id","subj":"144","obj":"Tax:2697049"},{"id":"A145","pred":"tao:has_database_id","subj":"145","obj":"Tax:694009"},{"id":"A146","pred":"tao:has_database_id","subj":"146","obj":"Tax:2697049"},{"id":"A147","pred":"tao:has_database_id","subj":"147","obj":"Tax:694009"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"While SARS-CoV-2 shares higher whole-genome sequence identity with bat-SL-CoVZC45 and bat-SL-CoVZXC21 (88–89%) than with SARS-CoV-1 (79–82%), the RBD of SARS-CoV-2 is more similar to SARS-CoV-1 RBD [8,9]. In line with this, several research groups have demonstrated that SARS-CoV-2 utilises the same host receptor, angiotensin-converting enzyme 2 (ACE2), as SARS-CoV-1 for viral entry [3,16-18]. Due to its role in virus entry, the S protein has been the target for the generation of monoclonal antibodies (mAb)."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T76","span":{"begin":6,"end":14},"obj":"Disease"},{"id":"T77","span":{"begin":6,"end":10},"obj":"Disease"},{"id":"T78","span":{"begin":121,"end":129},"obj":"Disease"},{"id":"T79","span":{"begin":121,"end":125},"obj":"Disease"},{"id":"T80","span":{"begin":153,"end":161},"obj":"Disease"},{"id":"T81","span":{"begin":153,"end":157},"obj":"Disease"},{"id":"T82","span":{"begin":183,"end":191},"obj":"Disease"},{"id":"T83","span":{"begin":183,"end":187},"obj":"Disease"},{"id":"T84","span":{"begin":271,"end":279},"obj":"Disease"},{"id":"T85","span":{"begin":271,"end":275},"obj":"Disease"},{"id":"T86","span":{"begin":358,"end":366},"obj":"Disease"},{"id":"T87","span":{"begin":358,"end":362},"obj":"Disease"}],"attributes":[{"id":"A76","pred":"mondo_id","subj":"T76","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A77","pred":"mondo_id","subj":"T77","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A78","pred":"mondo_id","subj":"T78","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A79","pred":"mondo_id","subj":"T79","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A80","pred":"mondo_id","subj":"T80","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A81","pred":"mondo_id","subj":"T81","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A82","pred":"mondo_id","subj":"T82","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A83","pred":"mondo_id","subj":"T83","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A84","pred":"mondo_id","subj":"T84","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A85","pred":"mondo_id","subj":"T85","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A86","pred":"mondo_id","subj":"T86","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A87","pred":"mondo_id","subj":"T87","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"While SARS-CoV-2 shares higher whole-genome sequence identity with bat-SL-CoVZC45 and bat-SL-CoVZXC21 (88–89%) than with SARS-CoV-1 (79–82%), the RBD of SARS-CoV-2 is more similar to SARS-CoV-1 RBD [8,9]. In line with this, several research groups have demonstrated that SARS-CoV-2 utilises the same host receptor, angiotensin-converting enzyme 2 (ACE2), as SARS-CoV-1 for viral entry [3,16-18]. Due to its role in virus entry, the S protein has been the target for the generation of monoclonal antibodies (mAb)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T53","span":{"begin":67,"end":70},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9397"},{"id":"T54","span":{"begin":86,"end":89},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9397"},{"id":"T55","span":{"begin":391,"end":393},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T56","span":{"begin":415,"end":420},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T57","span":{"begin":442,"end":445},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"}],"text":"While SARS-CoV-2 shares higher whole-genome sequence identity with bat-SL-CoVZC45 and bat-SL-CoVZXC21 (88–89%) than with SARS-CoV-1 (79–82%), the RBD of SARS-CoV-2 is more similar to SARS-CoV-1 RBD [8,9]. In line with this, several research groups have demonstrated that SARS-CoV-2 utilises the same host receptor, angiotensin-converting enzyme 2 (ACE2), as SARS-CoV-1 for viral entry [3,16-18]. Due to its role in virus entry, the S protein has been the target for the generation of monoclonal antibodies (mAb)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T28","span":{"begin":71,"end":73},"obj":"Chemical"},{"id":"T29","span":{"begin":90,"end":92},"obj":"Chemical"},{"id":"T30","span":{"begin":315,"end":326},"obj":"Chemical"},{"id":"T31","span":{"begin":434,"end":441},"obj":"Chemical"}],"attributes":[{"id":"A28","pred":"chebi_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/CHEBI_74815"},{"id":"A29","pred":"chebi_id","subj":"T29","obj":"http://purl.obolibrary.org/obo/CHEBI_74815"},{"id":"A30","pred":"chebi_id","subj":"T30","obj":"http://purl.obolibrary.org/obo/CHEBI_48433"},{"id":"A31","pred":"chebi_id","subj":"T31","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"While SARS-CoV-2 shares higher whole-genome sequence identity with bat-SL-CoVZC45 and bat-SL-CoVZXC21 (88–89%) than with SARS-CoV-1 (79–82%), the RBD of SARS-CoV-2 is more similar to SARS-CoV-1 RBD [8,9]. In line with this, several research groups have demonstrated that SARS-CoV-2 utilises the same host receptor, angiotensin-converting enzyme 2 (ACE2), as SARS-CoV-1 for viral entry [3,16-18]. Due to its role in virus entry, the S protein has been the target for the generation of monoclonal antibodies (mAb)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T32","span":{"begin":0,"end":204},"obj":"Sentence"},{"id":"T33","span":{"begin":205,"end":395},"obj":"Sentence"},{"id":"T34","span":{"begin":396,"end":512},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"While SARS-CoV-2 shares higher whole-genome sequence identity with bat-SL-CoVZC45 and bat-SL-CoVZXC21 (88–89%) than with SARS-CoV-1 (79–82%), the RBD of SARS-CoV-2 is more similar to SARS-CoV-1 RBD [8,9]. In line with this, several research groups have demonstrated that SARS-CoV-2 utilises the same host receptor, angiotensin-converting enzyme 2 (ACE2), as SARS-CoV-1 for viral entry [3,16-18]. Due to its role in virus entry, the S protein has been the target for the generation of monoclonal antibodies (mAb)."}

{"project":"2_test","denotations":[{"id":"32700671-31987001-29327469","span":{"begin":199,"end":200},"obj":"31987001"},{"id":"32700671-32007145-29327470","span":{"begin":201,"end":202},"obj":"32007145"},{"id":"32700671-32015507-29327471","span":{"begin":386,"end":387},"obj":"32015507"},{"id":"32700671-14647384-29327472","span":{"begin":388,"end":390},"obj":"14647384"},{"id":"32700671-31996437-29327472","span":{"begin":388,"end":390},"obj":"31996437"},{"id":"32700671-32094589-29327472","span":{"begin":388,"end":390},"obj":"32094589"}],"text":"While SARS-CoV-2 shares higher whole-genome sequence identity with bat-SL-CoVZC45 and bat-SL-CoVZXC21 (88–89%) than with SARS-CoV-1 (79–82%), the RBD of SARS-CoV-2 is more similar to SARS-CoV-1 RBD [8,9]. In line with this, several research groups have demonstrated that SARS-CoV-2 utilises the same host receptor, angiotensin-converting enzyme 2 (ACE2), as SARS-CoV-1 for viral entry [3,16-18]. Due to its role in virus entry, the S protein has been the target for the generation of monoclonal antibodies (mAb)."}

{"project":"MyTest","denotations":[{"id":"32700671-31987001-29327469","span":{"begin":199,"end":200},"obj":"31987001"},{"id":"32700671-32007145-29327470","span":{"begin":201,"end":202},"obj":"32007145"},{"id":"32700671-32015507-29327471","span":{"begin":386,"end":387},"obj":"32015507"},{"id":"32700671-14647384-29327472","span":{"begin":388,"end":390},"obj":"14647384"},{"id":"32700671-31996437-29327472","span":{"begin":388,"end":390},"obj":"31996437"},{"id":"32700671-32094589-29327472","span":{"begin":388,"end":390},"obj":"32094589"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"While SARS-CoV-2 shares higher whole-genome sequence identity with bat-SL-CoVZC45 and bat-SL-CoVZXC21 (88–89%) than with SARS-CoV-1 (79–82%), the RBD of SARS-CoV-2 is more similar to SARS-CoV-1 RBD [8,9]. In line with this, several research groups have demonstrated that SARS-CoV-2 utilises the same host receptor, angiotensin-converting enzyme 2 (ACE2), as SARS-CoV-1 for viral entry [3,16-18]. Due to its role in virus entry, the S protein has been the target for the generation of monoclonal antibodies (mAb)."}